Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)
Recruiting
Observational Study
Osteoporosis, Postmenopausal
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 50 – 85
- Sex
- Female
- Study type
- Observational
- Participants needed
- 125 (estimated)
- Sponsor
- 424 General Military Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
A 24-month prospective, open-label, randomized, multicenter, multinational, non-inferiority pragmatic clinical trial evaluating zoledronate single or double infusion versus oral alendronate following denosumab
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
• Postmenopausal women treated with denosumab for 3 or more years who will reach osteopenia
Exclusion Criteria:
* a bone disease other than postmenopausal osteoporosis
* use of medications other than bisphosphonates or SERMS affecting bone metabolism during the last 12 months …
Contacts